Schrodinger, Inc. Stock Price, News & Analysis

Schrödinger (Nasdaq: SDGR) announced a 29% increase in Q2 2021 revenue to $29.8 million, with software revenue rising 15% to $24.1 million. The company reported a gross profit of $12 million, though overall operating expenses grew to $42.3 million, leading to a net loss of $34.6 million. Notably, Schrödinger has partnered with Zai Lab to co-develop an oncology program, and expects to submit up to three IND applications in 2022. The company anticipates full-year revenue between $124 million and $142 million. Cash and equivalents totaled $616.6 million as of June 30, 2021.

Schrödinger (Nasdaq: SDGR) and Zai Lab (Nasdaq: ZLAB; HKEX: 9688) have announced a collaboration to jointly discover, develop, and commercialize a novel oncology program targeting DNA damage response. Zai Lab will initially fund Schrödinger's research costs and lead global development post candidate selection. Schrödinger retains co-development rights in the U.S. and can earn up to $338 million in milestone payments, plus royalties on international sales. This partnership aims to leverage both companies' expertise to accelerate innovative cancer therapies.

Schrödinger (Nasdaq: SDGR) is set to host a conference call on August 12, 2021, at 8:30 a.m. ET to discuss its Q2 2021 financial results and provide a business update. The event will be accessible via webcast on their investor site. Schrödinger is known for its innovative physics-based software platform that facilitates the rapid discovery of novel therapeutics and materials, significantly reducing costs compared to traditional methods. The company collaborates with various sectors globally, leveraging its technology to enhance drug development.

Schrödinger, Inc. (Nasdaq: SDGR) is hosting its first annual Educator's Day, aimed at enhancing the role of computational tools in education. The event features discussions on the development of curricula for teaching chemical interactions and drug design using Schrödinger's software. Keynote speaker Dr. Brent R. Stockwell emphasizes the importance of modern curricula for today’s scientists. Schrödinger aims to fill the resource gap in hands-on learning by training educators and facilitating effective learning through innovative methods.

Schrödinger (Nasdaq: SDGR) announced the granting of stock options to 14 new employees on July 15, 2021, totaling 32,975 shares. These options, part of the 2021 Inducement Equity Incentive Plan, have an exercise price of $67.46, matching the closing stock price on the grant date. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years. This initiative aims to attract talent and is compliant with Nasdaq Listing Rule 5635(c)(4).

Schrödinger (Nasdaq: SDGR) is set to present at two investor conferences in July 2021. The first presentation will occur on July 20, 2021, at the Evercore ISI AI x Therapeutics Day at 1:30 PM ET. The second presentation is scheduled for July 28, 2021, at the SVB Leerink CybeRx Conference at 2:00 PM ET. Schrödinger's innovative physics-based software platform enhances the discovery of therapeutics and materials, allowing for faster and cost-effective development.

Schrödinger, Inc. (Nasdaq: SDGR) announced on June 13, 2021, the grant of non-statutory stock options for 32,850 shares to 14 new employees. This action, part of the 2021 Inducement Equity Incentive Plan, was aimed at encouraging the employees to join the company. Each option has an exercise price of $77.51, equal to the stock's closing price on June 11, 2021. The options vest over four years, with a portion vesting after the first year and the remainder in monthly installments thereafter. Schrödinger continues to leverage its software platform for innovative drug and materials discovery.

Schrödinger (Nasdaq: SDGR) announced its participation in two upcoming virtual conferences. Management will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 3:00 p.m. ET, followed by a presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 4:40 p.m. ET. Both presentations will be accessible on Schrödinger’s website under 'News & Events' for approximately 14 days. Schrödinger's innovative software platform accelerates the discovery of therapeutic and material solutions.

Schrödinger, Inc. (Nasdaq: SDGR) announced on May 15, 2021, the granting of stock options to 11 newly hired employees, totaling 22,775 shares. The options, part of the 2021 Inducement Equity Incentive Plan, have an exercise price of $61.24 per share and vest over four years. This initiative aims to attract talent by enhancing employment compensation. Schrödinger is known for its physics-based software platform that accelerates therapeutic and material discovery, aiding various sectors globally.